Home » Investor Relations

Investor Relations

Investor Relations
Investor Relations is your source for insight into the investor information of Ocimum Biosolutions. It is intended to help investors better understand Ocimum's business strategies, our financial results and key performance indicators.
Outsourced solutions for the genomics industry Excellent track record Differentiated approach Strong global team
  • Ability to leverage wide suite of products and services to provide customized complete “outsourcing solutions” in genomics

  • Comprehensive genomics solutions provider with service offerings that span Lab Sample and Data Management; Genomic Services such as Gene Expression, Genotyping, and Sequencing; and Bioinformatics (BioExpress®, ToxExpress®, and Data Analysis Suites)
  • Growth and Profitability - 180% top line CAGR over the last 3 years; profitable

  • Successful acquisition integration - The Company has successfully integrated both European and U.S. acquisitions, and leveraged its lower cost Indian operation to extract efficiencies

  • Innovators in Genomics research with over 65 patents filed and 6 granted
  • Customer relationships with 80% of the 25 largest Pharmaceutical/Biotech companies and several reputed research and academic institutions

  • Global Solution Delivery, leveraging presence in India, Europe and the United States

  • Global leverage of talent and optimal sourcing - Ocimum provides “best shoring”, with a capable scientific and technology workforce in the US, Europe and India
  • Experienced management team and deep bench of global scientific talent

  • Backed by blue-chip investors (IFC, Kubera Partners LLC)

  • Strong corporate governance with globally respected board members
Our Vision

In many ways, the Ocimum story runs parallel with the -OMICS growth. At Ocimum, as we believe that 'your needs have always defined our priorities'. Our growth plan and strategy has been envisioned to cater to changing and growing needs of the research community. Our latest acquisition of Gene Logic’s genomic division makes our group the most experienced commercial microarray facility. We are indebted to our growing list of global customers, who have trusted us over the years, referred us as partners in their R&D efforts. Majority of them return to us and have chosen us as their long term outsourcing partner for their ongoing programs. This has helped us continuously expand our portfolio and offer unique range of integrated solutions.

The Ocimum Story

Receive Email Alerts:

Sign up to receive e-mail alerts whenever we post new information to the site. Just enter your e-mail address and click Subscribe.

Enter your email address: